Pharming (ADR) (PHAR)
Commercializes rare-disease medicines while advancing a mitochondrial-disease program.
$11.21
At close+0.08 (+0.72%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
$0.10
Revenue estimate
$106.1M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Jul '25Nov '25Mar '26May '26Jul '26Nov '26
Reported$0.05−$0.22$0.06$0.10$0.07−$0.07$0.02Pending
Estimate$0.07−$0.25−$0.10$0.05$0.15$0.05$0.06$0.10
Surprise−28.6%+12.0%+160.0%+100.0%−53.3%−240.0%−68.3%—
RevenueReportedEstimate
Mar '25May '25Jul '25Nov '25Mar '26May '26Jul '26Nov '26
Reported$96.0M$86.7M$110.6M$97.3M$106.5M$72.4M$90.2MPending
Estimate$60.9M$72.7M$80.2M$98.2M$111.8M$92.1M$99.5M$106.1M
Surprise+57.5%+19.2%+37.9%−0.9%−4.7%−21.3%−9.4%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.10 | — | — |
| Jul 2026 | $0.06 | $0.02 | −68.3% |
| May 2026 | $0.05 | −$0.07 | −240.0% |
| Mar 2026 | $0.15 | $0.07 | −53.3% |
| Nov 2025 | $0.05 | $0.10 | +100.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Oct 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Aug 2021 | |||
| Apr 2021 | |||
| Mar 2021 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Jun 2015 | |||
| Mar 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | $0.10 | — | — | $106.1M | — | — | — |
| Jul 30, 2026 | $0.06 | $0.02 | −68.3% | $99.5M | $90.2M | −9.4% | −10.5% |
| May 7, 2026 | $0.05 | −$0.07 | −240.0% | $92.1M | $72.4M | −21.3% | +8.2% |
| Mar 12, 2026 | $0.15 | $0.07 | −53.3% | $111.8M | $106.5M | −4.7% | −4.2% |
| Nov 6, 2025 | $0.05 | $0.10 | +100.0% | $98.2M | $97.3M | −0.9% | +5.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Jul 31, 2025 | |||||||
| May 8, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Oct 24, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Oct 26, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 16, 2023 | |||||||
| Oct 27, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 17, 2022 | |||||||
| Aug 9, 2021 | |||||||
| Apr 7, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 | |||||||
| Mar 31, 2015 | |||||||